Vismodegib induces significant clinical response in locally advanced trichoblastic carcinoma

Area of Science:

• Dermatology
• Oncology
• Molecular Biology

Background:

• Advanced basal cell carcinoma and adnexal carcinomas pose significant therapeutic challenges, often lacking effective treatments for metastatic or unresectable cases.
• Conventional treatments like surgery, radiotherapy, and chemotherapy have limitations in efficacy and tolerance for advanced or metastatic skin cancers.
• Targeted therapies, such as sonic hedgehog pathway inhibitors, represent a novel strategy for previously untreatable malignancies.

Observation:

• A patient initially diagnosed with basal cell carcinoma presented with trichoblastic carcinoma.
• This patient received treatment with vismodegib, a targeted inhibitor of the sonic hedgehog pathway.
• A remarkable and effective response was observed in the patient following vismodegib treatment.

Findings:

• Vismodegib demonstrated significant efficacy in a patient with trichoblastic carcinoma.
• The observed response suggests vismodegib may be a valuable therapeutic agent for this rare skin malignancy.
• This case highlights the potential of targeted therapy in managing advanced adnexal carcinomas.

Implications:

• Vismodegib shows encouraging therapeutic potential for trichoblastic carcinoma, warranting further investigation.
• Clinical trials are needed to rigorously evaluate the efficacy and safety of vismodegib in trichoblastic carcinoma.
• Targeted inhibition of the sonic hedgehog pathway could offer new treatment avenues for rare and advanced skin cancers.